m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02381)
Name
TMP269
Synonyms
TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269
    Click to Show/Hide
Status
Investigative
Structure
Formula
C25H21F3N4O3S
InChI
1S/C25H21F3N4O3S/c26-25(27,28)22-31-20(32-35-22)17-7-4-8-18(13-17)21(33)29-15-24(9-11-34-12-10-24)23-30-19(14-36-23)16-5-2-1-3-6-16/h1-8,13-14H,9-12,15H2,(H,29,33)
InChIKey
HORXBWNTEDOVKN-UHFFFAOYSA-N
PubChem CID
53344908
TTD Drug ID
D0R7JA
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Histone deacetylase 5 (HDAC5)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Histone deacetylase 5 (HDAC5) is a therapeutic target for TMP269. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TMP269 through regulating the expression of Histone deacetylase 5 (HDAC5). [1], [2]
References
Ref 1 METTL3 stabilizes HDAC5 mRNA in an m(6)A-dependent manner to facilitate malignant proliferation of osteosarcoma cells. Cell Death Discov. 2022 Apr 8;8(1):179. doi: 10.1038/s41420-022-00926-5.
Ref 2 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.